4 Key Things Investors Should Know About Pfizer's Experimental COVID-19 Pill

Merck (NYSE: MRK) has been in the spotlight recently with the announcement of positive results for its COVID-19 pill developed with Ridgeback Biotherapeutics. Pfizer (NYSE: PFE) is also evaluating an oral COVID-19 therapy and could be hot on the heels of Merck. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss four key things investors should know about Pfizer's experimental COVID-19 pill.

Source Fool.com